Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Kinoshita, Yoshiaki ^a   Koga, Yasutaka ^b   Sakamoto, Atsuhiko ^a   Hidaka, Kouko ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTODIAGNOSIS; DRUG RESPONSE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE GENE; EGFR GENE; GENE; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT PLEURA EFFUSION; PHARMACOGENETICS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION;

EID: 84886695846     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-200867     Document Type: Article

References (12)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
2. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24.
3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
4. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5.
5. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-20. (Pubitemid 46630993)
6. Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007;57:359-64. (Pubitemid 47285416)
7. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53-7. (Pubitemid 34121146)
8. Yuan H, Gaber MW, Boyd K, et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006;66:860-6. (Pubitemid 44436715)
9. Kaneda H, Okamoto I, Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 2013;8:e32-3.
10. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011;37:624-31.
11. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7. (Pubitemid 39089780)
12. Dai Q, Ling YH, Lia M, et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapyresistant tumor cell lines. Clin Cancer Res 2005;11:1572-8. (Pubitemid 40315242)